The European Medicines Agency has validated a Type II Variation application for Daiichi Sankyo and AstraZeneca’s ENHERTU (trastuzumab deruxtecan) in combination with pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer. The submission is based on results from the global phase 3 DESTINY-Breast09 trial, which showed a statistically significant progression-free survival benefit compared to the current first-line regimen of taxane, trastuzumab, and pertuzumab (THP).

This validation signals the start of the EMA’s scientific review process and follows the U.S. Food and Drug Administration’s recent approval of the same combination. While this dual HER2-targeting strategy is not entirely novel, the potential clinical impact of replacing a taxane backbone with a high-potency antibody-drug conjugate (ADC) in the first-line setting could have ripple effects on both standard-of-care paradigms and downstream treatment sequencing across HER2-positive metastatic breast cancer.

What this EMA validation reveals about clinical positioning and regulatory confidence in ADC combinations

For a disease setting long dominated by the THP triplet, the validation of ENHERTU plus pertuzumab reflects a shift in regulatory openness to ADC-based intensification earlier in the treatment continuum. The DESTINY-Breast09 trial was designed to test whether substituting the cytotoxic component of THP with a targeted payload—without compromising efficacy or safety—could set a new first-line benchmark.

The EMA’s acceptance of the variation application does not imply approval but signals that the data package met the threshold for formal review. Regulators are now in a position to weigh the risk-benefit profile of combining two HER2-targeted agents—one a monoclonal antibody (pertuzumab), the other an ADC with a potent topoisomerase I inhibitor payload.

Clinicians tracking the field have noted that replacing taxane-based chemotherapy with ENHERTU may reduce traditional toxicity burdens like alopecia and neuropathy, while introducing a different set of risks, including interstitial lung disease. The regulatory decision will likely hinge not only on efficacy endpoints such as progression-free survival and overall response rates, but also on the durability of responses and safety signals emerging from longer-term follow-up.

How DESTINY-Breast09 differs from previous HER2 trials—and why it matters now

Unlike earlier ENHERTU studies such as DESTINY-Breast03 and DESTINY-Breast04, which targeted later-line or HER2-low disease populations, DESTINY-Breast09 is a first-line trial against an entrenched standard of care. The randomized, open-label design enrolled over 1,100 patients across five continents and stratified participants by prior treatment history, hormone receptor status, and PIK3CA mutation status.

Its tripartite structure—testing ENHERTU monotherapy, ENHERTU plus pertuzumab, and standard THP—provides a nuanced comparative landscape. However, the monotherapy arm remains blinded, with only the combination arm versus THP data disclosed so far.

That design leaves key unanswered questions about whether dual HER2 blockade with ENHERTU and pertuzumab is necessary to achieve the observed efficacy, or whether the ADC alone is sufficient. This becomes especially relevant when considering tolerability and cost, particularly in publicly funded health systems.

What this changes in the metastatic HER2-positive breast cancer treatment algorithm

If approved, ENHERTU plus pertuzumab would represent the first significant disruption to the frontline HER2-positive metastatic breast cancer landscape in over a decade. Since the CLEOPATRA trial established THP as the standard of care, no contender has unseated its position despite advances in HER2-targeted therapy.

Introducing ENHERTU earlier in the sequence may compress the window for other HER2-directed agents such as tucatinib and neratinib, traditionally used in later lines. Industry observers believe this could trigger a reevaluation of treatment sequencing, with a possible front-loading of ADCs and a shift toward CNS-penetrant TKIs in subsequent lines.

Further, a move away from taxane-based regimens could influence patient quality of life metrics and healthcare utilization patterns, including reductions in supportive care needs. This could be particularly important for health systems balancing clinical benefit with long-term economic sustainability.

What challenges remain in clinical adoption, safety profiling, and sequencing strategy

Despite the promise of improved efficacy, ENHERTU’s known toxicity profile—especially the risk of drug-related interstitial lung disease and pneumonitis—remains a critical concern. While phase 3 data demonstrated a manageable safety profile, post-marketing surveillance will play a crucial role in defining real-world risks.

Manufacturing scale-up for global demand, companion diagnostic alignment for HER2 status determination, and reimbursement negotiations across the EU member states also remain operational hurdles. Analysts suggest that broader adoption may be uneven across regions depending on national formulary access, pricing strategy, and institutional comfort with ADC delivery logistics.

There is also strategic ambiguity around what the new approval, if granted, would mean for the monotherapy arm still under analysis. Should ENHERTU monotherapy also meet efficacy endpoints, clinicians may face complex decisions balancing dual-agent efficacy with single-agent tolerability, particularly in older or comorbid patients.

How this fits into the broader ADC landscape and Daiichi Sankyo’s oncology strategy

Daiichi Sankyo has positioned ENHERTU as the flagship of its proprietary DXd ADC platform, co-developed with AstraZeneca. The company has aggressively pursued label expansions across HER2-expressing solid tumors, including breast, lung, gastric, and colorectal cancers, anchoring its oncology growth around ADC science.

This first-line HER2-positive metastatic breast cancer indication would deepen ENHERTU’s entrenchment across the treatment continuum and strengthen Daiichi Sankyo’s ADC credibility as competitors such as Seagen (now part of Pfizer) and ImmunoGen expand their own platforms.

The DESTINY-Breast09 validation also has indirect implications for Daiichi Sankyo’s broader pipeline, which includes HER3- and TROP2-targeted ADCs. Success in this indication could bolster regulatory confidence in the DXd payload and linker system, easing the path for follow-on assets in development.

What European oncologists and regulators are likely to focus on next

As the Committee for Medicinal Products for Human Use begins its review, European stakeholders will be attuned to several core questions. These include how ENHERTU plus pertuzumab compares in terms of CNS metastases control, real-world toxicity, and treatment discontinuation rates versus THP.

Regulatory watchers also point to the growing importance of biomarker stratification, particularly in distinguishing HER2-high versus HER2-low expression within metastatic disease settings. Precision eligibility criteria will be key to maximizing therapeutic benefit while avoiding overtreatment.

Finally, questions of drug pricing and access remain front and center. While innovation is welcomed, the European market often imposes tougher reimbursement gatekeeping compared to the United States. Whether Daiichi Sankyo and AstraZeneca adopt a value-based access model or tiered pricing remains to be seen.

  ADCs, antibody-drug conjugate, AstraZeneca, CHMP review, Daiichi Sankyo, DESTINY-Breast09, Enhertu, European Medicines Agency, HER2-positive metastatic breast cancer, mBC, oncology, pertuzumab, trastuzumab deruxtecan, Type II Variation